CLINICAL TRIALS PROFILE FOR PROMETRIUM

All Clinical Trials for PROMETRIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00152438 ↗	Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone	Unknown status	University of British Columbia	Phase 2	2005-09-01	The primary purpose of this study is to determine the effects of a full dose (300 mg at hs) of oral micronized progesterone (OMP) on vasomotor symptoms [VMS] (hot flushes/night sweats), on forearm blood flow and on lipid levels and blood pressure in menopausal women without cardiovascular disease and with moderate to severe VMS. The hypotheses are that progesterone will improve hot flushes, increase endothelium-dependent forearm blood flow and will decrease blood pressure without change in lipid levels.
NCT00154180 ↗	Kronos Early Estrogen Prevention Study (KEEPS)	Unknown status	Albert Einstein College of Medicine	Phase 4	2005-09-01	The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗	Kronos Early Estrogen Prevention Study (KEEPS)	Unknown status	Albert Einstein College of Medicine of Yeshiva University	Phase 4	2005-09-01	The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗	Kronos Early Estrogen Prevention Study (KEEPS)	Unknown status	Brigham and Women's Hospital	Phase 4	2005-09-01	The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗	Kronos Early Estrogen Prevention Study (KEEPS)	Unknown status	Columbia University	Phase 4	2005-09-01	The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗	Kronos Early Estrogen Prevention Study (KEEPS)	Unknown status	Mayo Clinic	Phase 4	2005-09-01	The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.
NCT00154180 ↗	Kronos Early Estrogen Prevention Study (KEEPS)	Unknown status	University of California, San Francisco	Phase 4	2005-09-01	The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.

Clinical Trial Conditions for PROMETRIUM

Condition Name

Condition Name for PROMETRIUM
Intervention	Trials
Menopause	5
Suicidal Ideation	3
Cocaine Abuse	2
Preterm Birth	2

Condition MeSH

Condition MeSH for PROMETRIUM
Intervention	Trials
Amenorrhea	4
Premature Birth	3
Suicidal Ideation	3
Cocaine-Related Disorders	2

Clinical Trial Locations for PROMETRIUM

Trials by Country

Trials by Country for PROMETRIUM
Location	Trials
United States	111
Canada	5
Italy	1
Israel	1
Australia	1

Trials by US State

Trials by US State for PROMETRIUM
Location	Trials
North Carolina	11
California	8
Connecticut	7
Pennsylvania	5
Illinois	5

Clinical Trial Progress for PROMETRIUM

Clinical Trial Phase

Clinical Trial Phase for PROMETRIUM
Clinical Trial Phase	Trials
Phase 4	14
Phase 3	7
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for PROMETRIUM
Clinical Trial Phase	Trials
Completed	17
Recruiting	7
Unknown status	6

Clinical Trial Sponsors for PROMETRIUM

Sponsor Name

Sponsor Name for PROMETRIUM
Sponsor	Trials
National Institute of Mental Health (NIMH)	8
University of North Carolina, Chapel Hill	7
National Institute on Drug Abuse (NIDA)	7

Sponsor Type

Sponsor Type for PROMETRIUM
Sponsor	Trials
Other	68
NIH	25
Industry	5